P48.04 IMfirst; Phase IIIB Safety Study of Atezolizumab Plus Chemotherapy in a Real World Population of Untreated ES-SCLC

Abstract

survival (OS) respectively. Secondary endpoints include objective response rates, local and distant disease control, and quality of life/ patient reported outcomes assessment. Translational science component includes blood and tissue based immune related assays. Results: This study activated in May 2019. 120 of 506 planned patients have been accrued as of 8/20/2020.